.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AR23_AtazanavirAndRitonavir.AtazanavirAndRitonavir .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AR23_AtazanavirAndRitonavir.AtazanavirAndRitonavir| name: | AtazanavirAndRitonavir | |
| ATC code: | J05AR23 | route: | oral |
| compartments: | 1 | |
| dosage: | 300 | mg |
| volume of distribution: | 114 | L |
| clearance: | 8.64 | L/h |
| other parameters in model implementation | ||
Atazanavir and ritonavir is a fixed-dose combination of two antiretroviral drugs used in the treatment of HIV-1 infection in adults and pediatric patients. Atazanavir is a protease inhibitor used to prevent replication of HIV, while ritonavir acts as a pharmacokinetic enhancer by inhibiting CYP3A-mediated metabolism of atazanavir, thereby increasing its plasma concentrations. The combination is approved for clinical use and is used today as part of highly active antiretroviral therapy (HAART).
Mean pharmacokinetic parameters reported in healthy HIV-negative adult volunteers.